89 related articles for article (PubMed ID: 24413374)
21. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
22. [Molecular-target therapy for advanced malignant melanoma].
Takahashi S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):19-25. PubMed ID: 23306915
[TBL] [Abstract][Full Text] [Related]
23. Emerging BRAF inhibitors for melanoma.
Sabbatino F; Wang Y; Wang X; Ferrone S; Ferrone CR
Expert Opin Emerg Drugs; 2013 Dec; 18(4):431-43. PubMed ID: 24073999
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticle-mediated drug delivery for treating melanoma.
Mundra V; Li W; Mahato RI
Nanomedicine (Lond); 2015; 10(16):2613-33. PubMed ID: 26244818
[TBL] [Abstract][Full Text] [Related]
25. Successes and limitations of targeted cancer therapy in melanoma.
Romano E; Michielin O
Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988
[TBL] [Abstract][Full Text] [Related]
26. The current state of targeted therapy in melanoma: this time it's personal.
Smalley KS; McArthur GA
Semin Oncol; 2012 Apr; 39(2):204-14. PubMed ID: 22484192
[TBL] [Abstract][Full Text] [Related]
27. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract][Full Text] [Related]
28. [What is new in oncodermatology?].
Robert C
Ann Dermatol Venereol; 2008 Dec; 135 Suppl 7():S354-9. PubMed ID: 19264211
[TBL] [Abstract][Full Text] [Related]
29. Agents make "preferred list" in metastatic melanoma.
Thompson JA
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):785-7. PubMed ID: 24853217
[TBL] [Abstract][Full Text] [Related]
30. Melanoma: a model for testing new agents in combination therapies.
Ascierto PA; Streicher HZ; Sznol M
J Transl Med; 2010 Apr; 8():38. PubMed ID: 20406483
[TBL] [Abstract][Full Text] [Related]
31. Curing Stage IV Melanoma: Where Have We Been and Where Are We?
Chan PY; Corrie PG
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438654. PubMed ID: 38669609
[TBL] [Abstract][Full Text] [Related]
32. Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy.
Brys AK; Gowda R; Loriaux DB; Robertson GP; Mosca PJ
Biotechnol Adv; 2016; 34(5):565-577. PubMed ID: 26826558
[TBL] [Abstract][Full Text] [Related]
33. Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.
Kim E; Rebecca VW; Smalley KS; Anderson AR
Eur J Cancer; 2016 Nov; 67():213-222. PubMed ID: 27689717
[TBL] [Abstract][Full Text] [Related]
34. Better targeting melanoma: options beyond surgery and conventional chemotherapy.
Kyrgidis A; Valasidis A; Bourlidou E; Andreadis C
Recent Pat Endocr Metab Immune Drug Discov; 2011 May; 5(2):147-59. PubMed ID: 22074588
[TBL] [Abstract][Full Text] [Related]
35. Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era.
Izar B; Regan MM; McDermott DF
Cancer J; 2017; 23(1):63-67. PubMed ID: 28114257
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors: a milestone in the treatment of melanoma.
Wilden SM; Lang BM; Mohr P; Grabbe S
J Dtsch Dermatol Ges; 2016 Jul; 14(7):685-95. PubMed ID: 27373242
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of marine peptides in malignant melanoma.
Ahmed S; Alam W; Alsharif KF; Aschner M; Alzahrani FM; Saso L; Khan H
Environ Res; 2023 Jun; 227():115771. PubMed ID: 36967001
[TBL] [Abstract][Full Text] [Related]
38. Curing advanced melanoma by 2025.
Dummer R; Goldinger SM; Paulitschke V; Levesque MP
Curr Opin Oncol; 2015 Mar; 27(2):125-7. PubMed ID: 25646843
[TBL] [Abstract][Full Text] [Related]
39. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618965
[No Abstract] [Full Text] [Related]
40. Clinical trials: New options for melanoma?
Kirk R
Nat Rev Clin Oncol; 2012 May; 9(7):368. PubMed ID: 22641362
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
